SRPT – Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc. 是一家全资附属的生物制药公司,致力于发现和开发独特的基于RNA的稀有治疗感染疾病。采用该公司专有的平台技术,能够针对各种疾病和症状通过不同的RNA机体进行治疗。该公司致力于推进器杜氏肌营养不良症候选药物的开发,包括其主导候选产品——eteplirsen,目前正在llb临床试验阶段。该公司也致力于治疗感染性疾病的候选药物开发,包括其主导的针对马尔堡出血热病毒的候选药物,该公司已经受到并期望继续受到美国政府的研究合同。 Sarepta治疗方案公司于1980年7月22日成立与俄勒冈州。

中文介绍: https://xueqiu.com/S/SRPT

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta’s strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta’s product candidates are at an early stage of development.

英文介绍: https://www.morningstar.com/stocks/xnas/srpt/quote

主题测试文章,只做测试使用。发布者:star,转转请注明出处:http://wallstreetgm.com/srpt/

发表评论

邮箱地址不会被公开。 必填项已用*标注